Azilect

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2017
02420052017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Present anti-PD and -AD drugs have limited symptomatic activity and devoid of neuroprotective and neurorestorative property that… (More)
  • figure 1
Is this relevant?
2010
2010
Based on a multimodal drug design paradigm, we have synthesized a multifunctional non-toxic, brain permeable iron chelator, M30… (More)
Is this relevant?
2010
2010
Our recent studies demonstrated that propargylamine derivatives such as rasagiline (Azilect, Food and Drug Administration… (More)
  • figure 2
  • figure 3
  • figure 5
  • figure 4
  • figure 7
Is this relevant?
2010
2010
Rasagiline has been studied as a Parkinson disease (PD) neuroprotective agent in 2 major clinical trials, utilizing the delayed… (More)
Is this relevant?
2010
2010
Increasing evidence suggests that oxidative stress (OS)-induced pancreatic beta-cell impairments is involved in diabetes and… (More)
Is this relevant?
2009
2009
Novel therapeutic approaches for the treatment of neurodegenerative disorders comprise drug candidates designed specifically to… (More)
Is this relevant?
2008
2008
We recently reported that propargylamine derivatives such as rasagiline (Azilect) and its S-isomer TVP1022 are neuroprotective… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2007
2007
The anti-Parkinson monoamine oxidase (MAO)-B inhibitor rasagiline (Azilect) was shown to possess neuroprotective activities… (More)
Is this relevant?
2007
2007
The anti-Parkinson, selective irreversible monoamine oxidase B inhibitor drug, rasagiline (Azilect), recently approved by the US… (More)
Is this relevant?
Review
2006
Review
2006
  • The Medical letter on drugs and therapeutics
  • 2006
This Medicine Update is for people with Parkinson's disease who are taking, or thinking about taking, rasagiline. Independent… (More)
Is this relevant?